After Raymond James and H.C. Wainwright gave ADMA Biologics (NASDAQ: ADMA) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on ADMA Biologics yesterday and set a price target of $6.00. The company’s shares closed last Thursday at $1.51, close to its 52-week low of $1.38.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 22.2% and a 34.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on ADMA Biologics is a Strong Buy with an average price target of $6.00, a 287.1% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
ADMA Biologics’ market cap is currently $193.6M and has a P/E ratio of -2.00. The company has a Price to Book ratio of 1.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
Read More on ADMA:
- Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
- Marinus (MRNS) Received its Third Buy in a Row
- Analysts Offer Insights on Healthcare Companies: Catabasis Pharmaceuticals (CATB) and Clearside Biomedical (CLSD)
- H.C. Wainwright Sticks to Its Buy Rating for Entasis Therapeutics Holdings (ETTX)
- HTG Molecular Diagnostics (HTGM) Receives a Rating Update from a Top Analyst